Prodrug strategy for cancer cell-specific targeting: A recent overview

doi:10.1016/j.ejmech.2017.08.010

Review

. 2017 Oct 20:139:542-563.

doi: 10.1016/j.ejmech.2017.08.010. Epub 2017 Aug 4.

Prodrug strategy for cancer cell-specific targeting: A recent overview

Xian Zhang¹, Xiang Li², Qidong You³, Xiaojin Zhang⁴

Affiliations

¹ State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
² State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
³ State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Electronic address: youqd@163.com.
⁴ State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China; Department of Organic Chemistry, School of Science, China Pharmaceutical University, Nanjing 211198, China. Electronic address: zxj@cpu.edu.cn.

PMID: 28837920
DOI: 10.1016/j.ejmech.2017.08.010

Review

Prodrug strategy for cancer cell-specific targeting: A recent overview

Xian Zhang et al. Eur J Med Chem. 2017.

. 2017 Oct 20:139:542-563.

doi: 10.1016/j.ejmech.2017.08.010. Epub 2017 Aug 4.

Authors

Xian Zhang¹, Xiang Li², Qidong You³, Xiaojin Zhang⁴

Affiliations

¹ State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
² State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
³ State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Electronic address: youqd@163.com.
⁴ State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China; Department of Organic Chemistry, School of Science, China Pharmaceutical University, Nanjing 211198, China. Electronic address: zxj@cpu.edu.cn.

PMID: 28837920
DOI: 10.1016/j.ejmech.2017.08.010

Abstract

The increasing development of targeted cancer therapy provides extensive possibilities in clinical trials, and numerous strategies have been explored. The prodrug is one of the most promising strategies in targeted cancer therapy to improve the selectivity and efficacy of cytotoxic compounds. Compared with normal tissues, cancer cells are characterized by unique aberrant markers, thus inactive prodrugs targeting these markers are excellent therapeutics to release active drugs, killing cancer cells without damaging normal tissues. In this review, we explore an integrated view of potential prodrugs applied in targeted cancer therapy based on aberrant cancer specific markers and some examples are provided for inspiring new ideas of prodrug strategy for cancer cell-specific targeting.

Keywords: Cancer; Prodrug; Target therapy.

PubMed Disclaimer

Cited by

Asymmetric Primaquine and Halogenaniline Fumardiamides as Novel Biologically Active Michael Acceptors.
Rajić Z, Beus M, Michnová H, Vlainić J, Persoons L, Kosalec I, Jampílek J, Schols D, Keser T, Zorc B. Rajić Z, et al. Molecules. 2018 Jul 14;23(7):1724. doi: 10.3390/molecules23071724. Molecules. 2018. PMID: 30011922 Free PMC article.
On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site.
Vrettos EI, Mező G, Tzakos AG. Vrettos EI, et al. Beilstein J Org Chem. 2018 Apr 26;14:930-954. doi: 10.3762/bjoc.14.80. eCollection 2018. Beilstein J Org Chem. 2018. PMID: 29765474 Free PMC article. Review.
Combination of chemotherapy and oxidative stress to enhance cancer cell apoptosis.
Li X, Hou Y, Zhao J, Li J, Wang S, Fang J. Li X, et al. Chem Sci. 2020 Feb 25;11(12):3215-3222. doi: 10.1039/c9sc05997k. Chem Sci. 2020. PMID: 34122827 Free PMC article.
Tunable Methacrylamides for Covalent Ligand Directed Release Chemistry.
Reddi RN, Resnick E, Rogel A, Rao BV, Gabizon R, Goldenberg K, Gurwicz N, Zaidman D, Plotnikov A, Barr H, Shulman Z, London N. Reddi RN, et al. J Am Chem Soc. 2021 Apr 7;143(13):4979-4992. doi: 10.1021/jacs.0c10644. Epub 2021 Mar 24. J Am Chem Soc. 2021. PMID: 33761747 Free PMC article.
The expanding role of prodrugs in contemporary drug design and development.
Rautio J, Meanwell NA, Di L, Hageman MJ. Rautio J, et al. Nat Rev Drug Discov. 2018 Aug;17(8):559-587. doi: 10.1038/nrd.2018.46. Epub 2018 Apr 27. Nat Rev Drug Discov. 2018. PMID: 29700501 Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Prodrug strategy for cancer cell-specific targeting: A recent overview

Affiliations

Prodrug strategy for cancer cell-specific targeting: A recent overview

Authors

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources